Table 4

Summary of VEGF Trials

Trial

Patients

RR%

(CR/PR)

PFS

(months)

OS

(months)

Number

(patients)

Summary


Single Arm Phase 2

Perez et al. [61]

Carboplatin plus paclitaxel and bevacizumab in unresectable metastatic melanoma

17

6

12

53

Carboplatin plus paclitaxel and bevacizumab was well tolerated and clinically beneficial

Randomized Phase 2

Kim et al. [62]

Carboplatin plus paclitaxel and bevacizumab versus

Carboplatin plus paclitaxel in untreated metastatic melanoma

25.5

versus

16.4

5.6

versus

4.2

12.3

versus

8.6

214

Carboplatin plus paclitaxel and bevacizumab demonstrated statistically significant improvement in OS

Single Arm

Phase 2

Kottschade et al. [63]

Carboplatin plus nab-paclitaxel in chemotherapy naïve(CN) and previously treated (PT) metastatic melanoma

25.6 (CN)

8.8 (PT)

4.5 (CN)

4.1 (PT)

11.1 (CN)

10.1 (PT)

41 (CN)

35 (PT)

Carboplatin plus nab-paclitaxel has clinical activity in chemotherapy naïve patients

Single Arm Phase 2

Fruehauf et al. [64]

Axitiniba in metastatic melanoma after maximum on one prior therapy

18.8%

3.9

6.6

32

Axitinib demonstrated clinical activity in metastatic melanoma.


aAxitinib is an oral second-generation inhibitor of VEGF receptors 1, 2, and 3. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response RR, response rate.

Finn et al. BMC Medicine 2012 10:23   doi:10.1186/1741-7015-10-23

Open Data